<PAGE> 1
OMB APPROVAL
OMB NUMBER: 3235-0145
UNITED STATES Expires: October 31, 1994
SECURITIES AND EXCHANGE COMMISSION Estimated average burden
Washington, D.C. 20549 hours per form ....... 14.90
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 5 )*
------
BIOCHEM INTERNATIONAL INC.
- -------------------------------------------------------------------------------
(Name of Issuer)
Common Stock ($0.02 par value)
- -------------------------------------------------------------------------------
(Title of Class Securities)
090585 10 0
-------------------------------
(CUSIP Number)
Stephen Marcus, Holleb & Coff, 55 E. Monroe St., Ste. 4100, Chicago, IL 60603
(312) 807-4600
- -------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive Notices
and Communications)
Filing per Rule 101(a)(2)(ii) of Regulation S-T
--------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) of (4), check the following box / /.
Check the following box if a fee is being paid with the statement / /. (A
fee is not required only if the report person: (1) has a previous statement on
file reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less or such class.)
(See Rule 13d-7)
Note: Six copies of this statement, including all exhibits, should be filed
with the Commission. See Rule 13d-1(a) for other parties to whom copies are to
be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
disclosures provided in prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
<PAGE> 2
CUSIP NO. 090585 10 0 Page 2 of 8 pages
----------------------- ---- ----
<TABLE>
<S><C>
- ------------------------------------------------------------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S OR I.R.S IDENTIFICATION NO. OF ABOVE PERSON
DS. MEDICAL PRODUCTS CO.
- ------------------------------------------------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / /
(b)/ /
- ------------------------------------------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- ------------------------------------------------------------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
N/A
- ------------------------------------------------------------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) / /
- ------------------------------------------------------------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
State of Illinois
- ------------------------------------------------------------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 9,985,000
SHARES --------------------------------------------------------------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY ---
EACH --------------------------------------------------------------------------------------------------------------------
REPORTING 9 SOLE DISPOSITIVE POWER
PERSON 9,985,000
WITH --------------------------------------------------------------------------------------------------------------------
10 SHARE DISPOSITIVE POWER
---
- ------------------------------------------------------------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9,985,000
- ------------------------------------------------------------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / /
- ------------------------------------------------------------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
76.4%
- ------------------------------------------------------------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO.
- ------------------------------------------------------------------------------------------------------------------------------------
</TABLE>
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
<PAGE> 3
CUSIP NO. 090585 10 0 Page 3 of 8 pages
----------------------- ---- ----
<TABLE>
<S><C>
- ------------------------------------------------------------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S OR I.R.S IDENTIFICATION NO. OF ABOVE PERSON
KEN M. DAVEE
- ------------------------------------------------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / /
(b)/ /
- ------------------------------------------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- ------------------------------------------------------------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
N/A
- ------------------------------------------------------------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) / /
- ------------------------------------------------------------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
U.S.
- ------------------------------------------------------------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF - 0 -
SHARES --------------------------------------------------------------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 9,985,000
EACH --------------------------------------------------------------------------------------------------------------------
REPORTING 9 SOLE DISPOSITIVE POWER
PERSON - 0 -
WITH --------------------------------------------------------------------------------------------------------------------
10 SHARE DISPOSITIVE POWER
9,985,000
- ------------------------------------------------------------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9,985,000
- ------------------------------------------------------------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / /
- ------------------------------------------------------------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
76.4%
- ------------------------------------------------------------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
- ------------------------------------------------------------------------------------------------------------------------------------
</TABLE>
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
<PAGE> 4
CUSIP NO. 090585 10 0 Page 4 of 8 pages
----------------------- ---- ----
<TABLE>
<S><C>
- ------------------------------------------------------------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S OR I.R.S IDENTIFICATION NO. OF ABOVE PERSON
DAVID H. SANDERS
- ------------------------------------------------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / /
(b)/ /
- ------------------------------------------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- ------------------------------------------------------------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
N/A
- ------------------------------------------------------------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) / /
- ------------------------------------------------------------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
U.S.
- ------------------------------------------------------------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 76,900
SHARES --------------------------------------------------------------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 9,985,000
EACH --------------------------------------------------------------------------------------------------------------------
REPORTING 9 SOLE DISPOSITIVE POWER
PERSON 76,900
WITH --------------------------------------------------------------------------------------------------------------------
10 SHARE DISPOSITIVE POWER
9,985,000
- ------------------------------------------------------------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10,061,900
- ------------------------------------------------------------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / /
- ------------------------------------------------------------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
77.0%
- ------------------------------------------------------------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
- ------------------------------------------------------------------------------------------------------------------------------------
</TABLE>
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
<PAGE> 5
Page 5 of 8 pages
---- ----
THIS AMENDMENT NO. 5 TO SCHEDULE 13D IS FILED FOR THE PURPOSE OF RESTATING, IN
FORM APPROPRIATE FOR ELECTRONIC FILING, ALL CURRENTLY ACCURATE AND PERTINENT
INFORMATION HERETOFORE CUMULATIVELY FILED UNDER COVER OF THIS SCHEDULE 13D, FOR
PURPOSES OF COMPLYING WITH RULE 101 OF REGULATION S-T. OTHER THAN WITH RESPECT
TO THE STATEMENT OF RESERVATION APPEARING IN ITEM 4 HEREOF, THIS AMENDMENT NO.
5 REFLECTS NO SUBSTANTIVE CHANGES IN THE INFORMATION PROVIDED CUMULATIVELY AND
AS AMENDED BY AND THROUGH AMENDMENT NO. 4 HERETO.
SCHEDULE 13D
(AMENDMENT NO. 5)
ITEM 1. SECURITY AND ISSUER.
Title and Class of Securities: Common stock, $.02 par value.
Name and Address of Principal Executive Offices of the Issuer:
Biochem International Inc. (referred to herein as "Biochem"),
W238 N1650 Rockwood Drive, Waukesha, Wisconsin 53188-1199.
ITEM 2. IDENTITY AND BACKGROUND.
Person Filing:
(a-1) Name: DS Medical Products Co. (referred to herein as
"DS Medical")
(b-1) State of Incorporation: Illinois
(c-1) Principal Business: The design, development,
manufacture and sale of medical products and
investment in the securities of one or more companies
engaging in such activities. Address of Principal
Business and Principal Office: c/o Ken M. Davee, 180
East Pearson Street, Chicago, Illinois 60611.
(d-1) DS Medical has not, during the last five years, been
convicted in a criminal proceeding.
(e-1) DS Medical was not, during the last five years, a
party to any civil proceeding as a result of which it
was or is subject to a judgment, decree or final
order enjoining
<PAGE> 6
Page 6 of 8 pages
---- ----
future violations of, or prohibiting or mandating activities
subject to, federal or state securities laws or finding any
violation with respect to such laws.
(f-1) Citizenship: Not applicable.
Executive Officers, Directors and Controlling Persons of DS
Medical. [THIS SCHEDULE 13D IS FILED ON BEHALF OF THE
FOLLOWING INDIVIDUALS, AS WELL, PURSUANT TO RULE 13D-1(F)]
(a-2) Names: Ken M. Davee and David H. Sanders.
(b-2) Business Addresses: The business address for Mr.
Davee is 180 East Pearson Street, Chicago, Illinois
60611, and for Mr. Sanders is Biochem International
Inc., W238 N1650 Rockwood Drive, Waukesha, Wisconsin
53188-1199.
(c-2) Present Principal Occupations:
Name Principal Occupation
---- --------------------
Ken M. Davee President, Secretary and director
of DS Medical, Secretary and a director of
Biochem International Inc., and a private
investor
David H. Sanders Chairman, Chief Executive Officer,
Treasurer, and director of Biochem
International Inc., and Treasurer and
director of DS Medical
(d-2) No executive officer, director or controlling person
of DS Medical listed above has, during the last five
years, been convicted in a criminal proceeding.
(e-2) No executive officer, director or controlling person
of DS Medical listed above was, during the last five
years, a party to any civil proceeding as a result of
which he was or is subject to a judgment, decree or
final order enjoining future violations of, or
prohibiting or mandating activities subject to,
federal or state securities laws or finding any
violation with respect to such laws.
<PAGE> 7
Page 7 of 8 pages
---- ----
(f-2) Citizenship: The executive officers, directors and
controlling persons of DS Medical listed above are
citizens of the United States of America.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
The shares that are the subject of this Schedule 13D were
acquired with the personal funds of the reporting persons.
ITEM 4. PURPOSE OF TRANSACTION.
DS Medical is the investment vehicle through which Ken M.
Davee and David H. Sanders own a controlling interest in the
stock, and control the business, of Biochem.
While Biochem is not presently engaged in any negotiations or
discussions with any parties proposing an acquisition of
Biochem or its business or assets, management and the
principal beneficial shareholders of Biochem have, from time
to time, been approached by parties proposing such an
acquisition (see Biochem Reports on Form 8-K, dated May 23,
1995 and July 25, 1995), and Biochem and the reporting persons
hereunder reserve the right to solicit, initiate, entertain,
consider, discuss and negotiate offers for the sale or other
transfer of the stock or assets of Biochem from time to time.
The ownership of a significant majority of the outstanding
capital stock of Biochem by the reporting persons hereunder
and related parties, means that any such discussions,
negotiations and transfer could be accomplished when, as and
on terms deemed advantageous to those principal shareholders,
which may not coincide with the interests or anticipated
timing of minority shareholders.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
DS Medical is the record and beneficial owner of 9,985,000
shares of Biochem common stock, representing 76.4% of the
number of shares of the class outstanding.
Ken M. Davee, who owns 50%, and David H. Sanders, who may be
deemed the beneficial owner of 46.44%, of the common stock of
DS Medical, share voting and investment power over the Biochem
stock owned by DS Medical and, therefore, for purposes of Rule
13d-3 of the Securities and Exchange Commission, each may be
deemed to beneficially own such shares.
<PAGE> 8
Page 8 of 8 pages
---- ----
Mr. Sanders individually owns of record 76,900 shares of
Biochem common stock, representing approximately 0.5% of the
number of shares of the class outstanding.
If individual share ownership is combined with the aggregate
number of shares deemed to be beneficially owned through DS
Medical, Mr. Davee may be deemed to have beneficial ownership
of 76.4%, and Mr. Sanders may be deemed to have beneficial
ownership of 77.0%, of the outstanding shares of common stock
of the issuer.
For all purposes hereunder, the percent of class calculation
is based on a total of 13,070,084 shares issued and outstanding.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT
TO SECURITIES OF THE ISSUER.
None.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.
The parties' signatures hereto evidence their agreement that
this statement is filed on behalf of each of them as required
by Rule 13d-1(f).
SIGNATURE
After reasonable inquiry and to the best of our knowledge and belief, each
of the undersigned certify that the information set forth in this statement is
true, complete and correct.
Each of the undersigned hereby agrees that this statement is filed on
behalf of each of them pursuant to Rule 13d-1(f).
Dated: _____________, 1996 DS MEDICAL PRODUCTS CO.
By:___________________________
Ken M. Davee, President
______________________________
Ken M. Davee
______________________________
David H. Sanders
